RCT: In adults with Covid-19 and severe hypoxemia, 12 mg vs. 6 mg of Dexamethasone did not result in a statistically significant difference in the number of days alive without life support.
22 Oct, 2021 | 10:32h | UTCEditorial: Glucocorticoid Dose in COVID-19: Lessons for Clinical Trials During a Pandemic – JAMA
Commentary on Twitter
In a randomized trial of patients with #COVID19 and severe hypoxemia, compared with 6 mg of dexamethasone, 12 mg of dexamethasone did not statistically significantly reduce the number of days alive without life support at 28 days https://t.co/BMgLTel4aU pic.twitter.com/WKwI8xCUYO
— JAMA (@JAMA_current) October 21, 2021